Carfilzomib in ALL

CHOP, in collaboration with Onyx Therapeutics, Inc., isconducting a study for children and young adults up to 21 years old, with relapsedor refractory acute lymphoblastic leukemia. This clinical trial is adding thestudy drug, Carfilzomib, to a standard relapse chemotherapy regimen. For moreinformation about this study, including specific eligibility criteria, pleasevisit clinicaltrials.gov and search for "NCT02303821". To hear moreabout this and other available trails or get any questions answered pleasecontact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.